Zimmer Biomet’s Billion-Dollar Acquisition Reshapes Orthopedic Landscape

The orthopedic device sector has witnessed a significant consolidation with Zimmer Biomet Holdings’ complete acquisition of Paragon 28, a former market favorite specializing in foot and ankle solutions. This strategic move has permanently altered the financial structure of the once-independent company, marking a pivotal moment in its corporate history.

Trading of Paragon 28 shares ceased on the New York Stock Exchange effective April 21, 2025, following the finalization of the merger with Gazelle Merger Sub I, a wholly-owned subsidiary of Zimmer Biomet. The company now operates as a fully integrated unit within the larger medical technology conglomerate, resulting in the immediate suspension of its stock listing post-transaction.

Transaction Structure and Shareholder Compensation

The acquisition, valued at approximately $1.2 billion, delivered immediate value... Read more...